[Skip to Navigation]
Sign In
Comment & Response
September 24, 2020

Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge

Author Affiliations
  • 1Graduate School, Beijing University of Chinese Medicine, Beijing, China
  • 2Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, China
JAMA Oncol. 2020;6(11):1813. doi:10.1001/jamaoncol.2020.3946

To the Editor Recently, with the increasing research on immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs), recurrence of irAEs after ICI rechallenge has deserved more attention. In their cohort study, Dolladille and colleagues1 retrospectively assessed safety in patients with cancer who resumed therapy with the same ICIs and found that ICI rechallenge was associated with a recurrence of the same irAEs in one-quarter to one-third of the cases. However, there are some suggestions of this study that ought to be carefully considered, especially considering its promising research future as to ICIs.

Add or change institution